載入...

Tadalafil therapy for sarcoidosis-associated pulmonary hypertension

Abstract. Sarcoidosis-associated pulmonary hypertension (SAPH) is estimated to occur in at least 5% or more of sarcoidosis patients, and it contributes to significant morbidity and mortality. Optimal therapy for SAPH is not well established. We performed a 24-week open-label trial of tadalafil for S...

全面介紹

Na minha lista:
書目詳細資料
發表在:Pulm Circ
Main Authors: Ford, H. J., Baughman, R. P., Aris, R., Engel, P., Donohue, J. F.
格式: Artigo
語言:Inglês
出版: University of Chicago Press 2016
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5210066/
https://ncbi.nlm.nih.gov/pubmed/28090299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/688775
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!